Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2019

01-07-2019 | Pazopanib | Short Communication

18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer

Authors: Akira Toriihara, Heying Duan, Holly M. Thompson, Sonya Park, Negin Hatami, Lucia Baratto, Alice C. Fan, Andrei Iagaru

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2019

Login to get access

Abstract

Purpose

The usefulness of positron emission tomography/computed tomography (PET/CT) using (18F)-2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid peptide [PEG3-E{c(RGDyk)}2] (18F-FPPRGD2) in patients with metastatic renal cell cancer (mRCC) has not been evaluated; therefore, we were prompted to conduct this pilot study.

Methods

Seven patients with mRCC were enrolled in this prospective study. 18F-FPPRGD2 and 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) PET/CT images were evaluated in a per-lesion analysis. Maximum standardized uptake value (SUVmax) and tumor-to-background ratio (T/B) were measured for all detected lesions, both before and after starting antiangiogenic therapy.

Results

Sixty lesions in total were detected in this cohort. SUVmax from 18F-FPPRGD2 PET/CT was lower than that from 18F-FDG PET/CT (4.4 ± 2.9 vs 7.8 ± 5.6, P < 0.001). Both SUVmax and T/B from 18F-FPPRGD2 PET/CT decreased after starting antiangiogenic therapy (SUVmax, 4.2 ± 3.2 vs 2.6 ± 1.4, P = 0.003; T/B, 3.7 ± 3.2 vs 1.5 ± 0.8, P < 0.001). Average changes in SUVmax and T/B were − 29.3 ± 23.6% and − 48.1 ± 28.3%, respectively.

Conclusions

18F-FPPRGD2 PET/CT may be an useful tool for monitoring early response to antiangiogenic therapy in patients with mRCC. These preliminary results need to be confirmed in larger cohorts.
Appendix
Available only for authorised users
Literature
1.
Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:804–34.CrossRef
2.
Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, et al. Glioblastoma multiforme recurrence: an exploratory study of 18F FPPRGD2 PET/CT. Radiology. 2015;277:497–506.CrossRefPubMed
3.
Minamimoto R, Karam A, Jamali M, Barkhodari A, Gambhir SS, Dorigo O, et al. Pilot prospective evaluation of 18F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer. Eur J Nucl Med Mol Imaging. 2016;43:1047–55.CrossRefPubMed
4.
Iagaru A, Mosci C, Shen B, Chin FT, Mittra E, Telli ML, et al. 18F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients. Radiology. 2014;273:549–59.CrossRefPubMed
5.
Withofs N, Signolle N, Somja J, Lovinfosse P, Nzaramba EM, Mievis F, et al. 18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: correlation with histopathology. J Nucl Med. 2015;56:361–4.CrossRefPubMed
6.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed
7.
Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, et al. Comparison of integrin αvβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008;49:22–9.CrossRefPubMed
8.
Yoon HJ, Kang KW, Chun IK, Cho N, Im SA, Jeong S, et al. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2014;41:1534–43.CrossRefPubMed
9.
Withofs N, Martinive P, Vanderick J, Bletard N, Scagnol I, Mievis F, et al. [18F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:654–62.CrossRefPubMed
10.
Shenoy N, Pagliaro L. Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective. Ann Oncol. 2016;27:1685–95.CrossRefPubMed
Metadata
Title
18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer
Authors
Akira Toriihara
Heying Duan
Holly M. Thompson
Sonya Park
Negin Hatami
Lucia Baratto
Alice C. Fan
Andrei Iagaru
Publication date
01-07-2019
Publisher
Springer Berlin Heidelberg
Keyword
Pazopanib
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04295-7

Other articles of this Issue 7/2019

European Journal of Nuclear Medicine and Molecular Imaging 7/2019 Go to the issue

Original Article

Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI

Original Article

Clinical utility of 68Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma

Letter to the Editor

18F-FDG uptake of brown fat and cancer: casualty or causality?

Original Article

PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy

Editorial Commentary

Time for new imaging and therapeutic approaches in cardiac amyloidosis

Image of the Month

One-stop shopping 18F-FDG PET/CT in a patient with vascular type Behçet’s disease